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1. Introduction 
1.1 Background 
Encapsulating peritoneal sclerosis (EPS) is a devastating and potentially life threatening 
complication of peritoneal dialysis (PD). EPS was first described in 1980 and is characterised 
by progressive peritoneal fibrosis and thickening with encasement of bowel loops (Ghandi 
el al 1980). EPS results from chronic intra-abdominal inflammation and fibrosis but the 
trigger for this is unknown. The aetiology is thought to be multi-factorial. Early clinical 
studies identified acetate dialysate and chlorhexidine as causes (Slingeneyer 1987, Oules et 
al 1983). However, despite the removal of these causal factors from clinical practice, EPS 
continues to occur. The duration of exposure to PD therapy represents the most consistent 
“risk factor” identified in studies to date (Kawanishi et al 2001, Kawanishi et al 2004, Rigby 
et al 1998, Brown MC et al 2009). 
1.2 Diagnosis of EPS 
The clinical features of EPS have been described in previous clinical studies (Kawanishi et al 
2001, Kawanishi et al 2004, Rigby et al 1998, Nomoto et al 1996, Summers et al 2005, Brown 
MC et al 2009). The progressive peritoneal fibrosis compromises bowel motility and 
absorption, ultimately causing bowel obstruction (often sub-acute) and severe malnutrition. 
Typically EPS is also associated with progressive loss of ultrafiltration, causing fluid 
accumulation. Ascites may also develop (Perks et al 2004). 
The clinical, radiological and pathological criteria for the diagnosis of EPS have been 
defined by the International Society for Peritoneal Dialysis (ISPD) in 2000 (Kawaguchi et al 
2000) and these criteria should be met by all patients included in clinical and 
epidemiological studies in the post millennium. EPS may be diagnosed while the patient is 
on PD but many cases become apparent after stopping PD including after renal 
transplantation (Fieren et al 2007, Korte et al 2007, de Freitas DG et al 2007) Brown MC et al 
2009).  
1.3 “Incidence” of EPS 
EPS is an infrequent complication in patients after more prolonged exposure to PD but the 
exact incidence is unknown. Most previous studies are from Japan/Northeast Asia, where the 
duration of PD therapy tends to be longer. Multi-centre studies from Japan report “incidence” 
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rates of 0.8-2.5% of PD patients (Kawanishi et al 2001, Kawanishi et al 2004, Nomoto et al). 
Whether the findings from these studies can be extrapolated to Western populations and 
practice is uncertain. A recent case series from the UK identified 27 cases of EPS, representing 
an “incidence” of 3.3% in their PD population over 7 years (Summers et al 2005). An earlier 
Australian case series identified 54 cases over 14 years, representing an “incidence” of 0.7% 
(Rigby et al 1998). The data from these studies is summarised in Table 1 below. 
 
 
Study 
 
Country 
Year of 
publication 
 
Nomoto
et al 
 
Japan 
1996 
 
Rigby 
et al 
 
Australia
1998
 
Lee 
et al 
 
Korea 
2003 
 
Kawanishi
et al 
 
Japan 
2001 
 
Kawanishi
et al 
 
Japan 
2004 
 
Summers 
et al. 
 
UK 
2005 
 
Brown 
MC 
et al. 
UK 
2009 
Number of 
EPS Cases* 
62 54 (46) 31 17 48 27 (23) 46 
Dates of 
Study 
1980 - 1994 1980 - 1994 1981 - 2002 1999 - 20011999 - 2003 1998 – 2003 2000-2007 
Denominator 
Population  
(prevalent + 
incident 
patients) 
6923 7374 3888 2216 1958 810 1638 
Overall 
“Incidence” 
0.9% 0.7% 0.8% 0.8% 2.5% 3.3% 2.8% 
Mean PD 
Exposure 
(yrs) 
5.1 4.3 5.8 10 4.3 6.1 5.4 
Mortality 
(over study 
period) 
43.5 % 56 % 25.8 % 35 % 37.5 % 29.6 % 56.5% 
* The number of EPS cases who did not meet the ISPD 2000 criteria for EPS is shown in brackets in the 
second row of Table 1. 
 
Table 1. “Incidence” of EPS reported from previous studies 
1.4 Incidence of EPS 
The true incidence of EPS has been difficult to establish because: 
EPS is uncommon,  
EPS is associated with poor survival rates,  
misdiagnosis or delayed diagnosis of EPS may occur, especially if the patient develops 
symptoms after PD has been discontinued, 
most epidemiological studies describing the “incidence” of EPS have been retrospective.   
In addition most previous studies have included both incident and prevalent patients on PD 
on the start date of follow up which does not allow an accurate calculation of incidence 
(Kawanishi et al 2001, Kawanishi et al 2004, Rigby et al 1998, Nomoto et al 1996, Summers et 
al 2005). To calculate a true incidence of EPS a cohort of patients must be followed from the 
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start of PD to identify all cases diagnosed thereafter. To address this we reported the 
incidence of EPS in all patients starting PD in Scotland in the time period 01 January 2000 - 
31 December 2007 (Brown MC et al 2009). The rate of EPS in this study was 1.5% (19 EPS 
cases observed in 1238 incident PD patients) or an incidence of 4.9 per 1000 person years. 
This study showed that the incidence of EPS was 0% in first year of PD, rising progressively 
to 8.1% (CI 3.6-17.6) at >4-5 years; 8.8% (CI 3.2-23.1) at >5-6 years and 5.0% (CI 1.2-23.8) at >6 
years PD exposure (Table 2).  It is possible that greater awareness of EPS may have led to 
increased diagnosis of milder cases but the mortality rate was similar to rates reported in 
previous studies (Table 1) and was 42% at 1 year after diagnosis. 
 
Cumulative PD 
Exposure 
PD Cohort 
(n=1238) 
EPS Cases 
(n=19) 
Incidence 
(%) 
95% Confidence 
Intervals 
< 1 year 480 0 0 0 
1-2 years 326 2 0.6 0.2 - 2.1 
2-3 years 202 4 2.0 0.8 - 5.0 
3-4 years 114 4 3.5 1.4 - 8.7 
4-5 years 62 5 8.1 3.6 - 17.6 
5-6years 34 3 8.8 3.2 - 23.1 
> 6 years 20 1 5.0 1.2 - 23.8 
Table 2. Incidence rates of EPS related to total duration of PD exposure (not necessarily 
continuous) 
It is noticeable that there is a dramatic increase in the proportion of patients developing EPS 
after 4 years of PD (1 in 12 patients at risk).  Thus analysis of this incident PD patient cohort 
up to December 2007 showed that the incidence of EPS increased significantly with PD 
duration but the confidence limits of the observed incidence of EPS were wide as the 
number of cases of EPS was low and the PD patient follow up was relatively short. 
However, 806 patients (66%) of the PD cohort had had less than 2 years PD exposure by the 
end of 2007 so the incidence of EPS in this patient cohort is likely to increase after longer 
follow up. This could be addressed by reporting the incidence of EPS in this same cohort of 
PD patients after a longer period of follow up. 
1.5 Study aims 
The primary aims of the current study were: 
a. describe all of the cases of encapsulating peritoneal sclerosis (EPS) occurring between 01 
January 2000 – 30 June 2009 in the above cohort of patients who had commenced 
peritoneal dialysis (PD) in Scotland between 01 January 2000 - 31 December 2007  
b. calculate the true incidence of EPS in this PD cohort. 
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2. Methods 
2.1 Patients 
The cohort of patients aged over 18 years who started peritoneal dialysis (PD) between 
01 January 2000 and 31 December 2007 in Scotland (n= 1238) was identified from the Scottish 
Renal Registry. We sent each of the 10 adult renal units in Scotland a list of their patients in 
this cohort and a note of the diagnostic features of EPS.  We asked them to identify known 
or potential cases diagnosed after 01 January 2000. All units were originally approached in 
the summer of 2006 and at intervals thereafter.  
2.2 Inclusion criteria for EPS diagnosis 
Casenotes and electronic patient records for each possible case were examined by one data 
collector (MC Brown) to ensure all met the ISPD diagnostic criteria (Kawaguchi et al 2000). 
To confirm the diagnosis of EPS a patient had to have: 
clinical features and  
either typical radiological and/or  
histopathological features.   
Clinical features include abdominal pain, nausea, vomiting, abdominal distension, anorexia, 
weight loss, unexplained/resistant anaemia, unexplained fever, elevated inflammatory 
markers, loss of ultrafiltration, bowel obstruction and/or unexplained ascites.  Typical 
radiological features include ascites, typically loculated with multiple strands or septations, 
peritoneal thickening, thickening of bowel wall, calcification, thickened mesentery and/or 
matted bowel in the central abdomen. Positive pathology included the typical macroscopic 
appearance at laparotomy or laparoscopy or biopsy consistent with EPS with gross 
interstitial thickening with loss of mesothelium.  
2.3 Exclusion criteria for EPS diagnosis 
Exclusion criteria for EPS were met if there was an alternative explanation for the above 
findings: 
previous bowel perforation,  
TB,  
cirrhosis,  
intraperitoneal (IP) malignancy/chemotherapy,  
VP shunt or TIPSS,  
IP lavage with disinfectant or talc contamination 
2.4 Calculation of EPS incidence rates 
We have assumed that the individual units had adequate systems locally to identify patients 
diagnosed with EPS since 2000. In addition we looked for EPS in the European Dialysis and 
Transplantation Association (EDTA) coded causes of death in the Scottish Renal Registry 
records to identify any additional cases. To calculate the incidence and rates per time on PD 
we have only included patients who developed EPS and who were first exposed to PD after 
01 January 2000. The rates are given as the incidence with the 95% confidence intervals. 
All cases have been used to describe the clinical presentation. Cases of EPS in this national 
cohort of incident patients on PD were used to calculate incidence rates between 01 January 
2000 and 30 June 2009. Statistical analyses were performed using SPSS®. The incidence of 
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EPS was calculated as number of EPS cases divided by number of patients at risk, taking 
into account the person-time during which events were observed and time elapsed before 
EPS diagnosis.  
2.5 PD- associated peritonitis 
Peritonitis was defined as a PD effluent white cell count above 100 per mm3. Peritonitis rates 
were calculated as the number of patient months on PD divided by number of infections 
and expressed as number of months between episodes.  
3. Results 
3.1 Patient demographics 
31 of the 1238 patient cohort had developed EPS before 30 June 2009. The median duration 
of PD before the diagnosis of EPS was 4.0 years (interquartile range 2.9-5.2 years). The mean 
duration of exposure to PD of the patients who did not develop EPS was 1.8 years. The rate 
of peritonitis in the patients with EPS was 1 episode every 19.2 months which is very similar 
to the peritonitis rate in Scotland 2000-2009 (Scottish Renal Registry Report 2009).  
The clinical details of the 31 patients who developed EPS have been compared with the 
patients who did not develop EPS in Table 3 below. 
 
Patient demographics 
EPS Cases 
(n=31) 
PD Cohort 
(n=1207) 
Median Age (IQR) 53.9  (43 - 64) years 55 (45 - 70) years 
Proportion male 58% 55% 
Proportion Caucasian 94.8% >95% 
Median number of 
peritonitis episodes (IQR) 
2 (1-4) 1 ( 1-2) 
Table 3. Summary of demographics of patients who did and did not develop EPS 
The interquartile ranges (IQR) of median values are recorded in brackets. 
3.2 Clinical presentation 
Most patients had more than one clinical feature attributable to EPS. All patients had at least 
one of these three symptoms: abdominal pain, vomiting and/or abdominal distension (with 
ascites or in the context of bowel obstruction).   
3.3 Patient outcomes 
By the study end on 30th June 2009, 22 patients (71.0%) had died. 13 (60.0%) deaths were 
attributable to EPS. Median survival from diagnosis was 116 days (range 1-660 days, IQR 20-
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297 days). The “survivors” had a median of 1076 days follow-up since diagnosis (range 63-
1764 days, IQR 537-1309 days).  Overall the mortality rate was 54.8% at one year after 
diagnosis. 
3.4 Incidence of EPS 
We identified 31 EPS cases in the patient cohort giving an incidence of EPS of 2.5% in this 
patient cohort with a minimum follow up of 1.5 years. We searched the SRR database (for 
International Classification of Disease codes; ICD-9/ICD-10) reported in hospital discharge 
statistics but no additional cases were found.   
The incidence according to the duration of PD exposure is shown in Table 4. The incidence 
rates of EPS are higher than published previously, particularly for duration of PD exposure 
<5 years.  
 
Cumulative PD 
Exposure 
PD Cohort 
(n=1238) 
EPS Cases 
(n=31) 
Incidence 
 
 
95% Confidence 
Intervals 
< 1 year 470 1 0.2 % 0.1 - 1.1 
1-2 years 327 3 0.9 % 0.3 - 2.6 
2-3 years 198 5 2.5 % 1.1 - 5.8 
3-4 years 117 6 5.1 % 2.4 - 10.7 
4-5 years 63 6 9.5 % 4.5 - 19.3 
5-6 years 35 6 17.1 % 8.2 - 32.8 
> 6 years 28 4 14.3 % 5.8 - 31.7 
Table 4. Incidence of EPS related to duration of PD exposure 
3.5 Other possible “risk factors” 
14 patients (45.2 %) had used high strength dextrose (3.86% or equivalent) at some point 
during PD treatment. 29 (93.5 %) patients had used Extraneal (Icodextrin). There was no 
obvious relationship to any specific brand of PD dialysate fluid. The incidence of peritonitis 
was similar in the patients who did and did not develop EPS. 3 of the patients who 
developed EPS had never had peritonitis. The spectrum of organisms causing peritonitis 
was comparable between the EPS cases and the PD population unaffected by EPS.  
4. Discussion 
4.1 Incidence of EPS 
The main aim of this study was to calculate an accurate incidence of EPS and so establish the 
risk of EPS for patients starting PD in Scotland. This report provides a more definitive 
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evaluation of the incidence of EPS since all of the patients in this PD cohort have a minimum 
of 1.5 years follow up. Our study was retrospective until June 2006 and prospective from 01 
July 2006 - 30 June 2009.  From previous studies it is apparent that EPS occurs very rarely if 
PD duration is under 18 months, and the average duration of PD exposure before the onset 
of EPS is 4-6 years (Kawanishi et al 2004, Rigby et al 1998, Nomoto et al 1996, Summers et al 
2005, Brown MC et al 2009).   Although the initial period of this study was retrospective we 
would expect that most cases would be reported after 2004 which is 2-3 years before we first 
contacted the units. In fact the first patients diagnosed from this PD cohort were in mid 
2004. If any cases before 2004 were missed this would mean that the rates we report are an 
underestimate.  We performed secondary checks of the SRR database for relevant diagnostic 
codes (EDTA cause of death and ICD-9 and ICD-10 codes) to identify any cases that may 
have been missed. However, we did not identify any other cases.  
It is known from previous data that EPS often develops after stopping PD. This means that 
more cases from our cohort may still develop EPS and the incidence we have reported 
should be regarded as the minimum risk of developing EPS after PD. For this reason we are 
continuing to follow up the 2000-2007 PD cohort prospectively.  
As our understanding of the aetiology of EPS remains poor large, prospective, multi-centred 
studies are required to address the clinical problems created by an apparently rising 
incidence of EPS. As clinicians we should be able to inform our patients of the significant 
risks associated with the treatments we administer. Our study allows quantification of the 
minimum risk of developing EPS in patients starting PD in the modern era.  
4.2 Duration of PD as a risk factor for EPS 
The figures reported in this study show a higher incidence of EPS after more than 3 years of 
PD therapy than in the earlier report after shorter follow up. This is at least in part due to 
the significantly more patients at risk with more than 3 years exposure to PD. The latest data 
suggest that after 4 years of PD therapy almost 1 in 10 patients will develop EPS.  Previous 
studies have reported rates at 4 years PD exposure of 5% in Australia and <1% in Japan 
(Rigby et al 1998, Nomoto et al 1996). It is difficult to determine whether the higher rates 
found in this study represent an increase in the true incidence and/or increased clinical 
awareness of EPS or whether it reflects differences in our study design compared to 
previous studies. When we utilise the same method of calculating the incidence of EPS 
(number of cases/incident and prevalent PD patients in time period) as in previous studies, 
the results shown in Table 1 indicate an apparently increasing rate of EPS in the more recent 
studies.  The rates in this report are comparable to a previous study from Manchester in the 
UK and to the overall incidence in the more recent studies from Japan (Kawanishi et al 2004, 
Summers et al 2005).  
The risk of developing EPS is inversely related to the technique failure rate. A large 
proportion of the patients in this study with a minimum follow up period of 1.5 years were 
only on PD for less than 1 year so would be at low risk of developing EPS. In contrast the 
small portion of patients who were maintained on PD for at least 4 years has a relatively 
high incidence of EPS (16 of the 126 at risk patients) (Table 4).  
4.3 Other risk factors for EPS 
The peritonitis rates in the previous report on this incident PD cohort also showed 
comparable peritonitis rates between those patients who developed EPS and those patients 
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who did not (Brown MC et al 2009). Similar peritonitis rates in patients who do and who do 
not develop EPS have also been shown in other studies (Hendriks et al 1997). A study of 111 
patients who developed EPS showed 12 patients had no previous peritonitis episodes, 28 
had one previous episode, 30 had two previous episodes and 33 had three or more previous 
episodes (Balasubramaniam G et al 2009). Peritonitis per se is therefore not a risk factor for 
the PD population although it has been reported that some patients develop an acute onset 
of EPS shortly after an episode of severe peritonitis (Summers et al 2005, Brown MC et al 
2009). 
All except two cases in our series had used Extraneal dialysate. It is very difficult to 
untangle whether this reflects ultrafiltration failure in the early stages of EPS or whether the 
use of such fluids somehow promotes the development of EPS. Only around half of the EPS 
patients had used high strength dextrose. Patients who develop EPS have been shown to 
have higher peritoneal transport rates and lower net ultrafiltration compared with matched 
control patients (Hendriks et al 1997) but peritoneal transport characteristics were not 
available in this study. It has been reported that patients with ultrafiltration failure, defined 
as net ultrafiltration less than 400ml after a 4 hour dwell time using 3.86% dialysis fluid, are 
at high risk of  developing EPS if PD is continued (Sampimon et al 2011).  In this recent 
study half of the patients with ultrafiltration failure who remained on PD for more than 3 
years developed EPS (Sampimon et al 2011). 
4.4 Screening for EPS 
EPS may have been under-recognised in PD patients in the past and a high index of 
suspicion is needed in long term PD patients with symptoms due to subacute obstruction or 
ascites. However, it is important to avoid misdiagnosis of EPS and therefore all cases must 
fulfill well defined criteria in reaching a diagnosis of EPS as in this study. 
At present radiological techniques are unable to establish a diagnosis of “early” EPS.  CT 
scans which were performed coincidentally in PD patients prior to development of EPS did 
not show features indicating developing EPS (Tarzi et al 2008). Thus there is no evidence 
that regular screening of long-term PD patients by radiological techniques would be able to 
detect pre-symptomatic EPS or beneficially alter PD management.   
Previous studies have suggested that 5 years should be the time-point for screening for EPS 
or discontinuing PD because of the risk of EPS (Nomoto et al 1996, Summers et al 2005, 
Kawaguchi et al. 2005).  By 5 years 21 of the 31 cases in our case series already had 
developed EPS indicating that screening for EPS (if a reliable screening test was available) 
would already have missed two thirds of the cases and two thirds of cases would have 
occurred before switching dialysis modality. The data in this study lend further support to 
the UK EPS and ISPD guidelines on EPS which state that the optimal approach to patients 
on long duration PD is currently unclear but routine pre-emptive switching to 
haemodialysis or screening for EPS after a specified time on PD are not recommended 
(Woodrow et al 2009, Brown E et al 2010). Indeed many of the cases of EPS in this study and 
other studies (Fieren et al 2007, Korte et al 2007, de Freitas DG et al 2007, Brown M et al 
2009) occurred after stopping PD. Thus pre-emptive switching to haemodialysis could 
potentially be associated with development of EPS rather than being preventive of EPS and 
at present there is no data showing any benefit from such a policy.  Furthermore modality 
switch from PD could have significant detrimental implications for some PD patients who 
have social or medical reasons for not commencing haemodialysis. 
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5. Conclusions 
Abdominal pain, vomiting, abdominal distension and weight loss are the most common 
symptoms at the time of diagnosis and the majority of patients in this series were diagnosed 
after stopping PD. Total time on PD was the main risk factor associated with EPS. Follow up 
of the PD patient cohort from 2000-2007 with a minimum patient follow up of 1.5 years has 
shown that symptomatic EPS developed in more than 1 in 10 of patients who received PD 
for at least 4 years.  
The incidence rates reported in this study are higher than previously reported and have 
implications for patient education during renal replacement planning. This data may be 
used to inform patients of the minimum risk of developing EPS after starting PD. 
6. Acknowledgements 
6.1 Assistance from colleagues 
The authors wish to express their thanks to the nurses, doctors and administrative staff of all 
the individual renal units for their assistance in identifying the cases of EPS and providing 
their clinical records. The authors also wish to thank the Scottish Renal Registry staff.  
6.2 Disclosure of conflicts of interest 
Dr. Robert Mactier wishes to declare the following potential conflicts of interest:  
Study investigator for multicentre research studies conducted by Roche, Amgen and Baxter,  
Member of the clinical advisory board for Baxter in 2005 and 2010  
Sponsorship to attend scientific meetings from Leo, Roche and Baxter 
To his knowledge, he has had no other direct support from the renal technology industry.  
Dr Michaela Brown does not have any conflicts of interest to declare. 
7. References 
Balasubramaniam G, Brown EA, Davenport A, et al., (2009). The Pan-Thames EPS study: 
treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial 
Transplant; 24(10):3209-15. Epub 2009 Feb 11. 
Brown E, Van Biesen W, Finkelstein F, et al., (2009). Length of time on peritoneal dialysis 
and encapsulating peritoneal sclerosis: position paper for ISPD. Peritoneal Dialysis 
Int ; 29:595-600  
Brown MC, Simpson K, Kerssens JJ, Mactier RA. (2009). Encapsulating peritoneal sclerosis in 
the new millennium: a national cohort study. Clin J Am Soc Nephrol; 4(7):1222-9  
de Freitas DG, Augustine T, Brown EA, et al., (UK EPS Group). (2007). Encapsulating 
peritoneal sclerosis following renal transplantation - the UK experience. Am J 
Transplant; 7 (Suppl 2): 163 
Fieren MWJA, Betjes MGH, Korte MR, et al., (2007). Posttransplant encapsulating peritoneal 
sclerosis: a worrying new trend? Perit Dial Int; 27(6):619-24  
Ghandi VC, Ing TS, Daugirdas JT, et al., (1980). Failure of peritoneal dialysis due to 
peritoneal sclerosis.  Arch Int Med; 140:1201-1203 
Hendriks PM, Ho-Dac-Pannekeet MM, van Gulik TM, et al., (1997). Peritoneal sclerosis in 
chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, 
and peritoneal transport characteristics. Perit Dial Int; 17(2):136-43 
www.intechopen.com
 
Progress in Peritoneal Dialysis 
 
166 
Kawaguchi Y, Kawanishi H, Mujais S, et al., (2000). Encapsulating Peritoneal Sclerosis: 
Definition, Etiology, Diagnosis and Treatment. Perit Dial Int; 20(S4):S43-55 
Kawanishi H, Long-Term Peritoneal Dialysis Study Group.  (2001). Encapsulating peritoneal 
sclerosis in Japan: prospective multicentre controlled study. Perit Dial Int; 21 
(S3):S67-71 
Kawanishi H, Kawaguchi Y, Fukui H, et al.,(2004). Encapsulating Peritoneal Sclerosis in 
Japan: A Prospective, Controlled, Multicentre Study.  Am J Kidney Dis; 44(4):729-737  
Kawaguchi Y, Saito A, Kawanishi H, et al., (2005). Recommendations on the management of 
encapsulating peritoneal sclerosis in Japan 2005: Diagnosis, predictive markers, 
treatment, and preventative measures.  Perit Dial Int; 25 (Suppl 4): S83-S95 
Korte MR, Yo M, Betjes MG, et al., (2007) Increasing incidence of severe encapsulating 
peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant; 22(8):2412-
2414  
Nomoto Y, Kawaguchi Y, Kubo H, et al., (1996). Sclerosing encapsulating peritonitis in 
patients undergoing continuous ambulatory peritoneal dialysis: a report of the 
Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis; 
20(3):420-7 
Oules R, Challah S, Brunner FP. (1988). Case-Control study to determine the cause of 
sclerosing peritoneal disease. Nephrol Dial Transplant; 3:66-9 
Perks FJ, Murchison JT, Gibson P, et al., (2004). Imaging findings in sclerosing encapsulating 
peritonitis. J R Coll Physicians Edinb; 34:116-119 
Rigby RJ, Hawley CM. (1998). Sclerosing peritonitis: the experience in Australia. Nephrol Dial 
Transplant; 13:154-159 
Sampimon DE, Coester AM, Struijk DG, Krediet RT. (2011). The time course of peritoneal 
transport parameters in peritoneal dialysis patients who develop encapsulating 
peritoneal dialysis. Nephrol Dial Transplant; 26(1):291-8. Epub 2010 Jun 21. 
Scottish Renal Registry Report 2009. http://www.srr.scot.nhs.uk/Publications/scottish-
renal-registry-report-2009-web-version.pdf 
Slingeneyer A, (1987). Preliminary report on a cooperative international study on sclerosing 
encapsulating peritonitis.  Contrib Nephrol; 57:239-47 
Summers AM, Clancy MJ, Syed F, et al., (2005).  Single-centre experience of encapsulating 
peritoneal sclerosis in patients on peritoneal dialysis for end stage renal failure.  
Kidney Int; 68:2381-2388 
Tarzi RM, Lim A, Moser S, et al., (2008). Assessing the validity of an abdominal CT scoring 
system in the diagnosis of encapsulating peritoneal sclerosis.  Clin J Am Soc Nephrol; 
3: 1702-1710  
Woodrow G, Augustine T, Brown EA, et al,, UK Encapsulating Peritoneal Sclerosis guidelines. 
http://www.renal.org/Libraries/Other_Guidlines/Encapsulating_Peritoneal_Scle
rosis_guidelines_UK_EPS_Group_Final_July_2009.sflb.ashx  
www.intechopen.com
Progress in Peritoneal Dialysis
Edited by Dr. Ray Krediet
ISBN 978-953-307-390-3
Hard cover, 184 pages
Publisher InTech
Published online 17, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Progress in Peritoneal Dialysis is based on judgement of a number of abstracts, submitted by interested
people involved in various aspects of peritoneal dialysis. The book has a wide scope, ranging from in-vitro
experiments, mathematical modelling, and clinical studies. The interested reader will find state of the art
essays on various aspects of peritoneal dialysis relevant to expand their knowledge on this underused
modality of renal replacement therapy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Robert Mactier and Michaela Brown (2011). Encapsulating Peritoneal Sclerosis in Incident PD Patients in
Scotland, Progress in Peritoneal Dialysis, Dr. Ray Krediet (Ed.), ISBN: 978-953-307-390-3, InTech, Available
from: http://www.intechopen.com/books/progress-in-peritoneal-dialysis/encapsulating-peritoneal-sclerosis-in-
incident-pd-patients-in-scotland
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
